Jump to content

Clomipramine

From Pharmacopedia
Revision as of 15:06, 14 May 2026 by MediaWiki default (talk | contribs) (Assign pharmacological categories from List_of_CNS-active_medicines)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
TCA, Antidepressant
Clomipramine
Anafranil

Experience

👥 No personal reports yet
No clinical reports yet

Log in to add your own experience.

Problems

No problems yet. Be the first to suggest one.

+ Add a problem

Titration strategies

No titration strategies yet. Be the first to suggest one.

+ Add a titration strategy

Effects

No effects listed yet. Be the first to suggest one.

+ Add an effect

Interactions

Pharmacogenomic + mechanism interactions20 edges
Pharmacogenomic guideline recommendationsCPIC and Dutch Pharmacogenetics Working Group clinical guidelines
Phenotype:CYP2D6 normal metabolizer monitor CPIC Strong 70 / 100
CPIC rec 8093679 [Strong]: Initiate therapy with recommended starting dose. CPIC pair-level B (CYP2D6, CYP2C19 and Tricyclic Antidepressants) [PMID 23486447, 27997040]
Phenotype:CYP2C19 normal metabolizer monitor CPIC Strong 70 / 100
CPIC rec 8093679 [Strong]: Initiate therapy with recommended starting dose. CPIC pair-level B (CYP2D6, CYP2C19 and Tricyclic Antidepressants) [PMID 23486447, 27997040]
Phenotype:CYP2D6 intermediate metabolizer avoid FDA Label 35 / 100
CPIC rec 8093642 [Optional]: Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended. CPIC pair-level B (CYP2D6, CYP2C19 and Tricyclic Antidepressants) [PMID 23486447, 27997040] FDA labeling (Precautions)
Phenotype:CYP2C19 poor metabolizer avoid CPIC B 35 / 100
CPIC rec 8093642 [Optional]: Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended. CPIC pair-level B (CYP2D6, CYP2C19 and Tricyclic Antidepressants) [PMID 23486447, 27997040]
Phenotype:cyp2c19 lpm avoid CPIC B 35 / 100
CPIC rec 8093662 [Optional]: Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended. CPIC pair-level B (CYP2D6, CYP2C19 and Tricyclic Antidepressants) [PMID 23486447, 27997040]
Phenotype:CYP2D6 normal metabolizer avoid FDA Label 35 / 100
CPIC rec 8093680 [Optional]: Avoid clomipramine use. If clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. CPIC pair-level B (CYP2D6, CYP2C19 and Tricyclic Antidepressants) [PMID 23486447, 27997040] FDA labeling (Precautions)
Phenotype:CYP2D6 poor metabolizer avoid FDA Label 35 / 100
CPIC rec 8093715 [Optional]: Avoid clomipramine use. If a clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended. CPIC pair-level B (CYP2D6, CYP2C19 and Tricyclic Antidepressants) [PMID 23486447, 27997040] FDA labeling (Precautions)
CPIC rec 8093715 [Optional]: Avoid clomipramine use. If a clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended. CPIC pair-level B (CYP2D6, CYP2C19 and Tricyclic Antidepressants) [PMID 23486447, 27997040]
Phenotype:CYP2C19 normal metabolizer avoid CPIC B 35 / 100
CPIC rec 8093716 [Optional]: Avoid clomipramine use. If a clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. CPIC pair-level B (CYP2D6, CYP2C19 and Tricyclic Antidepressants) [PMID 23486447, 27997040]
Phenotype:CYP2C19 rapid metabolizer avoid CPIC B 35 / 100
CPIC rec 8093718 [Optional]: Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended. CPIC pair-level B (CYP2D6, CYP2C19 and Tricyclic Antidepressants) [PMID 23486447, 27997040]
CPIC rec 8093719 [Optional]: Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended. CPIC pair-level B (CYP2D6, CYP2C19 and Tricyclic Antidepressants) [PMID 23486447, 27997040]
Phenotype:cyp2c19 lim avoid CPIC B 35 / 100
CPIC rec 8093721 [Optional]: Avoid clomipramine use. If a clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended. CPIC pair-level B (CYP2D6, CYP2C19 and Tricyclic Antidepressants) [PMID 23486447, 27997040]
Phenotype:CYP2D6 ultrarapid metabolizer avoid FDA Label 35 / 100
CPIC rec 8093724 [Optional]: Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended. CPIC pair-level B (CYP2D6, CYP2C19 and Tricyclic Antidepressants) [PMID 23486447, 27997040] FDA labeling (Precautions)
Phenotype:CYP2D6 intermediate metabolizer prefer alternative FDA Label 30 / 100
CPIC rec 8093646 [Optional]: Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended. CPIC pair-level B (CYP2D6, CYP2C19 and Tricyclic Antidepressants) [PMID 23486447, 27997040] FDA labeling (Precautions)
Phenotype:CYP2C19 rapid metabolizer prefer alternative CPIC B 30 / 100
CPIC rec 8093646 [Optional]: Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended. CPIC pair-level B (CYP2D6, CYP2C19 and Tricyclic Antidepressants) [PMID 23486447, 27997040]
Phenotype:CYP2C19 ultrarapid metabolizer prefer alternative CPIC B 30 / 100
CPIC rec 8093650 [Optional]: Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended. CPIC pair-level B (CYP2D6, CYP2C19 and Tricyclic Antidepressants) [PMID 23486447, 27997040]
Phenotype:CYP2D6 normal metabolizer prefer alternative FDA Label 30 / 100
CPIC rec 8093685 [Optional]: Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. CPIC pair-level B (CYP2D6, CYP2C19 and Tricyclic Antidepressants) [PMID 23486447, 27997040] FDA labeling (Precautions)
Phenotype:CYP2D6 intermediate metabolizer monitor CPIC B 20 / 100
CPIC rec 8093640 [Optional]: Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. CPIC pair-level B (CYP2D6, CYP2C19 and Tricyclic Antidepressants) [PMID 23486447, 27997040]
Phenotype:CYP2C19 intermediate metabolizer monitor CPIC B 20 / 100
CPIC rec 8093634 [Optional]: Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended. CPIC pair-level B (CYP2D6, CYP2C19 and Tricyclic Antidepressants) [PMID 23486447, 27997040]
Phenotype:cyp2c19 lim monitor CPIC B 20 / 100
CPIC rec 8093704 [Optional]: Initiate therapy with recommended starting dose. CPIC pair-level B (CYP2D6, CYP2C19 and Tricyclic Antidepressants) [PMID 23486447, 27997040]

Patient experience

Fluoxetine via Category:Antidepressants👤 exp n/a/5 outcome n/a (n=1)⚕️ exp 1.0/5 outcome +33.0 (n=1)

Relevant anecdote

No anecdotes yet. Share a relevant one.

+ Add an anecdote

Relevant Literature

No literature entries yet.

Log in to submit relevant literature.

Summary
Classes
TCA, Antidepressant
Common uses
Pharmacy
Pharmacology
Purported mechanism
Potent serotonin reuptake inhibitor; also NRI